echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Received US$3 billion from Roche to help develop gene therapies for diseases such as Alzheimer's disease

    Received US$3 billion from Roche to help develop gene therapies for diseases such as Alzheimer's disease

    • Last Update: 2021-09-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Today, Shape Therapeutics announced that it has reached a research and development cooperation and licensing agreement with Roche
    .


    It will use its RNA editing technology platform RNAfix and AAVid technology platform to develop gene therapies for the treatment of Alzheimer's disease, Parkinson's disease and rare diseases


    (The original text has been deleted)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.